Results 191 to 200 of about 27,163 (253)

Dermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up. [PDF]

Mult Scler J Exp Transl Clin
Samimi M, Sajedi A, Paybast S, Nabavi NS, Karimi S, Yazdanbakhsh S, Gaffari M, Najafian A, Faghani L, Zolfaghari Z, Vosough M, Nabavi SM.   +11 more
europepmc   +1 more source

Fingolimod for Multiple Sclerosis; Mechanism of Action, Safety and Toxicity

, 2016
Zahra Tolou–Ghamari, Hamid Mazdak
openalex   +1 more source

Serum visfatin in multiple sclerosis: distinct profiles in healthy controls, naive patients, and treated RRMS. [PDF]

Front Immunol
Mert S, Acır İ, Öztürk Emre H, Balcı K, Demir E.   +4 more
europepmc   +1 more source

Oral therapies for multiple sclerosis: fingolimod and cladribine

, 2011
Orhan Aktaş, Hans‐Peter Hartung
openalex   +1 more source

Exploring SARS-CoV‑2 Spike RBD Pockets as Targets for Generic Drugs: A Combined Computational, Biophysical, and Biological Approach. [PDF]

ACS Omega
García-Marín J, Francés-Gómez C, Forcada-Nadal A, Adhav A, Marco-Marín C, Rubio V, Marina A, Llácer JL, Geller R, Martín-Santamaría S.   +9 more
europepmc   +1 more source

Terápiás továbblépés dilemmája relapszáló-remittáló sclerosis multiplexben az első vonalbeli kezelés hatástalansága esetén: fingolimod vagy natalizumab? [PDF]

, 2014
Lovas, Gábor
core  

Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod

, 2018
R. Hernández Clares, Paloma Sánchez Pedreño, E. García Vázquez, Ester Carreón Guarnizo, José Eustasio Meca Lallana   +4 more
openalex   +1 more source

Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod

, 2015
Lee J, Han MH
openalex   +1 more source

Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis. [PDF]

Ophthalmol Sci
Wang WX, Rossmiller H, Getahun H, Santoki A, Perantie DC, Naismith RT, Apte RS.   +6 more
europepmc   +1 more source